Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2 | P10415 | 5/20 | 0.80 |
| ▸ | MEN1 | O00255 | 4/20 | 0.80 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.80 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.80 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.80 |
| ▸ | BAK1 | Q16611 | 1/20 | 0.80 |
| ▸ | MAPT | P10636 | 7/20 | 0.74 |
| ▸ | POLB | P06746 | 4/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.74 |
| ▸ | LMNA | P02545 | 1/20 | 0.74 |
| ▸ | GAA | P10253 | 1/20 | 0.74 |
| ▸ | ADAMTS5 | Q9UNA0 | 2/20 | 0.67 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | USP2 | O75604 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | THRB | P10828 | 1/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5970105 | 1.00 | BCL2 (0.80) | BCL2MEN1KMT2ABCL2L1MCL1 | |
| SCHEMBL13657863 | 0.93 | BCL2 (0.77) | BCL2MEN1KMT2ABCL2L1MCL1 | |
| SCHEMBL13219035 | 0.91 | BCL2 (0.67) | BCL2MEN1KMT2ABCL2L1MCL1 | |
| SCHEMBL13982547 | 0.90 | BCL2 (0.80) | BCL2MEN1KMT2ABCL2L1MCL1 | |
| SCHEMBL17655014 | 0.90 | BCL2 (0.65) | BCL2MEN1KMT2ABCL2L1MCL1 | |
| SCHEMBL13812532 | 0.90 | BCL2 (0.80) | BCL2MEN1KMT2ABCL2L1MCL1 | |
| SCHEMBL4264548 | 0.89 | BCL2 (1.00) | BCL2MEN1KMT2ABCL2L1MCL1 | |
| SCHEMBL14163443 | 0.89 | KMT2A (0.78) | BCL2MEN1KMT2ABCL2L1MCL1 | |
| SCHEMBL158041 | 0.89 | BCL2 (1.00) | BCL2MEN1KMT2ABCL2L1MCL1 | |
| SCHEMBL158040 | 0.89 | BCL2 (1.00) | BCL2MEN1KMT2ABCL2L1MCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190183948-A1 | USE OF BCL-XL INHIBITOR AND ONCOLYTIC VIRUS IN PREPARATION OF ANTITUMOR DRUG | GUANGZHOU VIROTECH PHARMACEUTICAL CO., LTD. (CN) | 2019-06-20 | — | — | US | disclosed |
| US-20060037091-A1 | Method for producing hypertrophic scarring animal model for identification of agents for prevention and treatment of human hypertrophic scarring | GURTNER GEOFFREY C | 2006-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190183948-A1 | USE OF BCL-XL INHIBITOR AND ONCOLYTIC VIRUS IN PREPARATION OF ANTITUMOR DRUG | BCL2L1, BCL2L13, BCL2L10 | BCL2 4/4885MEN1 864/4885KMT2A 1818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.